U.S. Markets closed

Nightstar Soars as Biogen to Buy Gene Therapy Company for $877 Million

Tony Owusu

Nightstar shares were up 66% to $25.16 in trading Monday. Biogen's offer for Nighstar is $25.50 a share. Nightstar makes gene therapy treatments for choroideremia, a rare, inherated eye disease that leads to blindness.